Antibody-mediated transduction of heat shock proteins into living cells

Abstract

The invention provides for a fusion protein comprising a 3E10 Fv joined to a Hsp-70, Hsp-27, Hsp-90 or GRP-78 or portion thereof, and optionally, the 3E10 Fv comprising an amino acid sequence AGIH at its amino terminus.

1 .- 2 . (canceled) 
     
     
         3 . A fusion protein comprising a 3E10 Fv joined to Hsp-27 or portion thereof, and optionally, the 3E10 Fv comprising an amino acid sequence AGIH at its amino terminus. 
     
     
         4 . The fusion protein of  claim 3  having a construct shown as His6-AGIH-Fv-myc-Hsp27 ( FIG. 12 ; SEQ ID NOS:1, 2, 3, 25, 26, or 27). 
     
     
         5 .- 6 . (canceled) 
     
     
         7 . A fusion protein comprising a 3E10 Fv attached/joined to a Hsp-90 or portion thereof, and optionally, the 3E10 Fv comprising an amino acid sequence AGIH at its amino terminus. 
     
     
         8 .- 10 . (canceled) 
     
     
         11 . The fusion protein of  claim 3 , wherein the 3E10 Fv is a derivative of monoclonal antibody 3E10 from 3E10 hybridoma (ATCC Accession No. PTA 2439 hybridoma) or an antibody that competes with monoclonal antibody 3E10. 
     
     
         12 .- 34 . (canceled) 
     
     
         35 . A pharmaceutical composition for treating a subject suffering from a disease or disorder comprising the fusion protein of  claim 3 , and pharmaceutically acceptable carriers, binders, diluents, adjuvants, excipients, and/or vehicles. 
     
     
         36 .- 47 . (canceled) 
     
     
         48 . A pharmaceutical composition for inhibiting a disease or disorder associated with hydrogen peroxide toxicity or reactive oxygen species (ROS) comprising the fusion protein of  claim 3 , and pharmaceutically acceptable carriers, binders, diluents, adjuvants, excipients, and/or vehicles. 
     
     
         49 .- 50 . (canceled) 
     
     
         51 . A method for inhibiting a disease or disorder by promoting hydrogen peroxide or reactive oxygen species (ROS) cytoprotection comprising administering the pharmaceutical composition of  claim 35 , thereby inhibiting the disease or disorder. 
     
     
         52 . A method for inhibiting or treating a subject suffering a disease or disorder comprising administering a suitable amount of the pharmaceutical composition of  claim 35  to the subject, thereby inhibiting or treating the disease or disorder. 
     
     
         53 . The method of  claim 51 , wherein the disease or disorder is acute renal failure, acute organ failure, liver injury, bowel infarction, peripheral vascular disease, pulmonary failure, or a cancer. 
     
     
         54 . The method of  claim 51 , wherein the disease or disorder is a brain injury, heart injury, skin injury or radiation injury. 
     
     
         55 . The method of  claim 54 , wherein the brain injury is a brain trauma, spinal cord injury, peripheral nerve injury, or stroke. 
     
     
         56 . The method of  claim 54 , wherein the heart injury is a myocardial infarction. 
     
     
         57 . The method of  claim 54 , wherein the skin injury is a wound, burn, or decubitus ulcer. 
     
     
         58 . The pharmaceutical composition of  claim 54 , wherein the radiation injury is a burn or poison. 
     
     
         59 . The fusion protein of  claim 3 , wherein the 3E10 Fv is replaced with a non 3E10 Fv which competes with the binding of 3E10 to its epitope. 
     
     
         60 . The pharmaceutical composition of  claim 35 , wherein the fusion protein is the fusion protein comprising a 3E10 Fv joined to a Hsp-70 or portion thereof, a 3E10 Fv joined to Hsp-27 or portion thereof, a 3E10 Fv attached/joined to a Hsp-90 or portion thereof or a 3E10 Fv attached/joined to GRP78 or portion thereof. 
     
     
         61 .- 126 . (canceled)